Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Total revenues	$ 54	$ 319	$ 806,431
Operating costs and expenses
Research and development	419,509	323,740	231,496
Acquired in-process research and development	70,000	0	0
Selling, general and administrative	126,206	103,218	77,616
Transaction costs	8,638	0	14,573
Total operating costs and expenses	624,353	426,958	323,685
(Loss) income from operations	(624,299)	(426,639)	482,746
Interest and other income (expense)
Interest income	1,428	11,052	26,872
Interest expense	(4,159)	(4,523)	(4,791)
Other (expense) income, net	(3,272)	2,421	3,061
Gain from Longboard equity method investment	13,869	12,955	0
Total interest and other income, net	7,866	21,905	25,142
(Loss) income before income taxes	(616,433)	(404,734)	507,888
Income tax provision	0	0	(110,333)
Net (loss) income	$ (616,433)	$ (404,734)	$ 397,555
Net (loss) income per share, basic:
Net (loss) per share, basic (dollars per share)	$ (10.14)	$ (7.39)	$ 7.99
Net (loss) per share, diluted (dollars per share)	$ (10.14)	$ (7.39)	$ 7.69
Net (loss) income per share, diluted:
Shares used in calculating net (loss) income per share, basic (in shares)	60,776,000	54,767,000	49,779,000
Shares used in calculating net (loss) income per share, diluted (in shares)	60,776,000	54,767,000	51,698,000
Comprehensive (Loss) Income:
Net (loss) income	$ (616,433)	$ (404,734)	$ 397,555
Foreign currency translation adjustment	188	161	(11)
Unrealized (loss) gain on available-for-sale investments	(1,168)	(764)	1,469
Comprehensive (loss) income	(617,413)	(405,337)	399,013
Collaboration and other revenue
Revenues
Total revenues	54	57	7,284
United Therapeutics revenue
Revenues
Total revenues	0	0	800,000
Royalty revenue
Revenues
Total revenues	$ 0	$ 262	$ (853)